Summary of Studies of Changes in Vascular Reactivity Caused by Natriuretic Hormones

References

• Doris P. A. Endogenous inhibitors of the Na,K pump. Miner and Electrolyte Metab 1996; 22: 303–10
   PubMedGoogle Scholar
• Hollenberg N. K., Graves S. W. Endogenous sodium pump inhibition: Current status and therapeutic opportunities. Prog in Drug Res 1996; 46: 9–42
   PubMedGoogle Scholar
• De Wardener H. E., Mills I. H., Clapham W. F., Hayter C. J. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci 1991; 21: 249–258
   Google Scholar
• Kramer H. J., Gonick H. C., Paul W. L., Lu E. Third factor: inhibitor of Na,K-ATPase?. Proc 4th International Congress of Nephrology, Stockholm, 1969; 1–373
   Google Scholar
• Buckalew V. M.J., Martinez F. J., Green W. E. The effect of dialysates and ultrafiltrates of plasma of saline-loaded dogs on toad bladder sodium transport. J Clin Invest 1970; 49: 926–935
   PubMed Web of Science ®Google Scholar
• Pamnani M. B., Huot S., Buggy J., Clough D., Haddy F. J. Demostration of a humoral inhibitor of the Na-K pump in some models of experimental hypertension. Hypertens 1981; 3(suppl II)96–101
   Google Scholar
• Blaustein M. P., Hamlyn J. M. Role of a natriuretic factor in essential hypertension: A hypothesis. Ann Intern Med 1983; 98: 785–792
   PubMed Web of Science ®Google Scholar
• Abel P. W., Urquilla P. R., Katsutoshi G., Westfall D. P., Robinson R. L., Fleming W. W. Chronic reserpine treatment alters sensitivity and membrane potential of the rabbit saphenous artery. J Pharmacol Exp Ther 1981; 217: 430–439
   PubMed Web of Science ®Google Scholar
• Hendrickx H., Casteels R. Electrogenic sodium pump in arterial smooth muscle cells. Pfleugers Arch. 1974; 346: 299–306
   PubMed Web of Science ®Google Scholar
• Fleming W. W. The electrogenic NA+,K+-pump in smooth muscle: Physiologic and pharmacologic significance. Annu. Rev. Pharmacol. Toxicol. 1980; 20: 129–149
   PubMed Web of Science ®Google Scholar
• Weber M. A., Elmar W., Gonick H. C., Prins B. A., Purdy R. E. Effects of a human-derived sodium transport inhibitor on in vitro vascular reactivity. Am J Hypertens 1989; 2: 754–761
   PubMed Web of Science ®Google Scholar
• Krep H. H., Graves S. W., Price D. A., Lazarus M., Ensign A., Soszynski P. A., Hollenberg N. K. Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with Digibind. Stoichiometry and its implications. Am J Hyperten Jan, 1996; 9(1)39–46
   PubMed Web of Science ®Google Scholar
• Haupert G. T., Carilli C., Cantley L. C. Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+,K+-ATPase. AM J Physiol 1984; 247: F919–924
   PubMed Web of Science ®Google Scholar
• Ferrandi M., Minotti E., Salardi S., Florio M., Bianchi G., Ferrari P. The ouabain-like factor in the Milan hypertensive rats. Am J Physiol 1992; 263: F739–748
   Google Scholar
• Janssens S. P., Kachoris C., Parker W. L., Hales C. A., Haupert G. T., Jr. Hypothalamic Na+,K+-ATPase inhibitor constricts pulmonary arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22(Suppl 2)S42–46
   Google Scholar
• Hallback M., Weiss L. Mechanisms of spontaneous hypertension in rats. Med Clin North A m 1977; 61: 593–609
   PubMed Web of Science ®Google Scholar
• Hamlyn J. M., Blaustein M. P., Bova S., Ducharme D. W., Harris D. W., Mandel F., Mathews W. R., Ludens J. H. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88: 6259–6263
   PubMed Web of Science ®Google Scholar
• Karaki H., Ozaki H., Urakawa N. Effects of Ouabain and potassium-free solution on the contraction of isolated blood vessels. Eur J Pharmacol 1978; 48: 439–443
   PubMed Web of Science ®Google Scholar
• LaBella F. S., Templeton J. F., Sashi Kumar V. P., Bose D. Progesterone derivatives that bind to the digitalis receptor. Trends Pharmacol. Sci 1989; 10: 11–14
   PubMed Web of Science ®Google Scholar
• Woolfson R. G., Graves J., LaBella F. S., Templeton J. F., Poston L. Effects of bufalin and pregnanes on vasoreactivity of human resistance arteries. Biochem Biophys res Commun 1992; 186: 1–7
   PubMed Web of Science ®Google Scholar
• Bagrov A. Y., Roukoyatkina N. I., Fedorova O. V., Pinaev A. G., Ukhanova M. V. Digitalis-like and vasoconstrictor effects of endogenous digoxin-like factor(s) from the venom of Bufo marinustoad. Eur J Pharmacol 1993; 234: 165–172
   PubMed Web of Science ®Google Scholar
• Bagrov A. Y., Roukoyatkina N. I., Pinaev A. G., Dmitrieva R. I., Fedorova O. V. Effects of two endogenous Na+,K+-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur J Pharmacol 1995; 274: 151–158
   PubMed Web of Science ®Google Scholar
• Bagrov A. Y., Dmitrieva R. I., Fedorova O. V., Kazakov G. P., Roukoyatkina N. I., Shpen V. M. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity. Am J Hypertens 1996; (10 pt 1): 982–990
   Google Scholar
• Xu Z., Mondal G., Song J. P., Purdy R. E. Effect of Ouabain on the rabbit ear artery contraction to serotonin: Enhanced response mediated by serotonergic rather than alphaadrenergic receptors. J Pharmacol Exp Ther 1993; 253(2)668–675
   Google Scholar
• Purdy R. E., Prins B. A., Weber M. A., Bakhtiarian A., Smith J. R., Kim M. K., Nguyen T. H., Weiler E. W. Possible novel action of ouabain: Allosteric modulation of vascular serotonergic (5-HT2) and angiotensinergic (AT1) receptors. J Pharmacol Exp Ther Oct, 1993; 267(1)228–237
   PubMed Web of Science ®Google Scholar
• Kaumann A. J., Frenken M. A paradox: The 5-HT2-receptor antagonist kentanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Naunyn-Schmiedeberg's Arch Pharmacol. 1985; 328: 295–300
   Google Scholar